Neumora Therapeutics, Inc. (NMRA)
0.4955
+0.01
(+1.75%)
USD |
NASDAQ |
Nov 06, 16:00
0.4955
0.00 (0.00%)
After-Hours: 16:56
Neumora Therapeutics Research and Development Expense (Annual) : 176.06M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 176.06M |
| December 31, 2024 | 200.93M |
| December 31, 2023 | 142.72M |
| December 31, 2022 | 91.75M |
| Date | Value |
|---|---|
| December 31, 2021 | 55.78M |
| December 31, 2020 | 17.61M |
| December 31, 2019 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| EyePoint, Inc. | 221.04M |
| Context Therapeutics, Inc. | 31.86M |
| LENZ Therapeutics, Inc. | 18.67M |
| BioAge Labs, Inc. | 73.97M |
| ANI Pharmaceuticals, Inc. | 51.66M |